Interview with MVI's Director of R&D
Rick King, PhD, looks at challenges and opportunities in malaria vaccine development and discusses the thinking behind MVI’s work in anti-infection and transmission-blocking vaccines.
Read more »
Photo credit: F. Beilhe
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.
Walking together: Steve Davis reflects on 15 years of Gavi partnership
This week on Gavi’s blog, Steve Davis, president and CEO of PATH, provided insight on what it takes to develop and strengthen a global community of scientists, policymakers, advocates, regulators, medical workers, and caregivers to continue our good work.
Malaria vaccine gets a shot in the arm
MVI announces $156 million grant from Bill & Melinda Gates Foundation to support essential vaccine role in strategy to eradicate malaria.
Japan's Global Health Innovative Technology Fund announces award to MVI
MVI welcomes announcement by Japan’s Global Health Innovative Technology Fund of a grant to MVI and its partner Ehime University to fast-track the development of a novel malaria vaccine candidate. The new vaccine approach is targeted at blocking malaria parasite transmission between humans and mosquitoes.
GSK announces EU regulatory submission for RTS,S malaria vaccine candidate
The regulatory application to the European Medicines Agency (EMA) will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state for a disease recognized by the World Health Organization as of major public health interest, but intended exclusively for use outside the EU.
Global Conference on Vaccines
April 13–15, 2015
"Investing in the future to defeat malaria.” 
Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
Twitter
Flickr